Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452981 | 0.93 | FASN (1.00) | FASNKDM4E | |
| SCHEMBL4457571 | 0.92 | FASN (0.85) | FASNKDM4E | |
| SCHEMBL4454406 | 0.91 | FASN (1.00) | FASN | |
| SCHEMBL4452964 | 0.91 | FASN (1.00) | FASNKDM4E | |
| SCHEMBL4459392 | 0.89 | FASN (1.00) | FASN | |
| SCHEMBL4456305 | 0.89 | FASN (1.00) | FASNKDM4E | |
| SCHEMBL4465138 | 0.88 | FASN (0.84) | FASN | |
| SCHEMBL4456307 | 0.87 | FASN (1.00) | FASN | |
| SCHEMBL4454841 | 0.87 | FASN (0.96) | FASN | |
| SCHEMBL4455780 | 0.86 | FASN (0.75) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | claimed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1981341-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | Merck and Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1830879-A4 | MRI GUIDED PHOTODYNAMIC THERAPY FOR CANCER | UNIV UTAH RES FOUND (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1830879-A2 | MRI GUIDED PHOTODYNAMIC THERAPY FOR CANCER | University of Utah Research Foundation (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006060797-A2 | MRI GUIDED PHOTODYNAMIC THERAPY FOR CANCER | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | FASN 1/4885KDM4E 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.